test
Sunday, June 23, 2024

Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data

Must read



Annexon shares rose 46% to $6.70 after hours as the company said it will present topline Phase 3 results for one of its flagship programs on Tuesday morning.



Source link

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article